OncRef
Skip to newsletter content
|
RCCFebruary 2026
0:00 / 3:02
Renal Cell Carcinoma — Monthly Compass
Feb 01–28, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in renal cell carcinoma this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
renal cell carcinoma updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • Adjuvant pembrolizumab plus belzutifan reduced the risk of recurrence or death by 28% versus pembrolizumab alone in clear‑cell RCC after nephrectomy, positioning HIF‑2α–PD‑1 doublet therapy to supersede PD‑1 monotherapy in high‑risk adjuvant care.
    • In previously treated advanced ccRCC post–anti‑PD‑(L)1 therapy, belzutifan plus lenvatinib improved median PFS to 14.8 months versus 10.7 months on cabozantinib (HR 0.70) with higher ORR, enabling immediate second‑line sequencing away from single‑agent TKIs.
  • Key Clinical Development Updates
    • The FDA accepted for review sNDAs for belzutifan plus lenvatinib in previously treated advanced RCC (PDUFA October 4, 2026) and granted priority review to adjuvant belzutifan plus pembrolizumab or KEYTRUDA QLEX for RCC with a clear‑cell component (PDUFA June 19, 2026), with both filings supported by LITESPARK‑011 and LITESPARK‑022 presented at ASCO GU 2026.
    • Telix held two FDA Type A meetings for TLX250‑CDx (Zircaix) in clear‑cell RCC to align on key issues for BLA resubmission and is completing agreed comparability and documentation deliverables while receiving approvals to commence kidney cancer trials such as LUTEON.
  • Important Clinical Trial Publications
    • In KEYMAKER‑U03 substudy 03A (Phase 1/2) for treatment‑naive advanced ccRCC, the triplet of pembrolizumab, lenvatinib, and belzutifan achieved a 77.5% ORR and 31.8‑month median PFS but performed similarly to the doublet control, with belzutifan’s incremental contribution being defined in the ongoing Phase 3 LITESPARK‑012 (NCT04626479).
  • Key Conference Updates
    • ASCO GU 2026 RCC presentations emphasized HIF‑2α–anchored intensification across adjuvant and post–PD‑(L)1 settings and the initial integration of CAIX‑targeted radiotherapeutics into TKI/IO combinations.
  • Emerging Themes & Macro-Trends
    • HIF‑2α is consolidating as a combination backbone across disease stages, with adoption dependent on proactive management of class‑specific anemia/hypoxia and the operational advantages of oral regimens.
    • CAIX‑directed radiotherapeutics and companion imaging are opening biomarker‑selected RCC segments, with trials like STARLITE‑1 advancing 177Lu‑girentuximab into triplet combinations for treatment‑naive advanced disease.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-02-01 and 2026-02-28 about renal cell carcinoma.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Telix Pharmaceuticals reported FY2025 results and stated it had held two FDA Type A meetings for TLX250-CDx (Zircaix) in clear cell RCC, aligning on key issues for a BLA resubmission; the company is completing agreed comparability and documentation deliverables for that resubmission. The update also noted regulatory approvals to commence kidney cancer trials (e.g., LUTEON) while TLX250-CDx advances toward U.S. filing resubmission. ¹ (read more)
  • Merck and Eisai announced the FDA accepted for review two supplemental NDAs for WELIREG (belzutifan) plus LENVIMA (lenvatinib) for certain previously treated adults with advanced RCC after anti–PD‑1/L1 therapy, assigning a PDUFA target action date of October 4, 2026. The sNDAs are supported by positive Phase 3 LITESPARK‑011 results presented at ASCO GU 2026. ² (read more)
  • Merck announced the FDA accepted for priority review supplemental applications for WELIREG plus KEYTRUDA (pembrolizumab) or KEYTRUDA QLEX as adjuvant therapy for adults with RCC with a clear cell component at increased risk of recurrence following nephrectomy, with a PDUFA target action date of June 19, 2026. The filings are supported by positive Phase 3 LITESPARK‑022 data presented at ASCO GU 2026. ³ (read more)
Conference
Major Conference Updates
Conference Information
  • 2026 ASCO Genitourinary Cancers Symposium; Moscone West, San Francisco, CA; February 26–28, 2026. (read more)
  • Overall sentiment: RCC data at ASCO GU 2026 emphasized HIF-2α–anchored intensification strategies across adjuvant and post–PD-(L)1 settings, with radiotherapeutics beginning to integrate into combination regimens.
  • Theme 1: Adjuvant HIF-2α–PD-1 Intensification in High-Risk ccRCC
    • Significance: Dual adjuvant therapy improved disease-free survival over PD-1 monotherapy, positioning combination adjuvant treatment as a potential new standard where recurrence risk remains substantial. (read more)
    • Mechanism insights / clinical impact: Adding the first-in-class HIF-2α inhibitor WELIREG (belzutifan) to KEYTRUDA (pembrolizumab) reduced the risk of recurrence or death by 28% (HR 0.72); toxicity reflects HIF-2α class effects (notably anemia/hypoxia) requiring monitoring but manageable with dose modifications. (read more)
    • Patient populations affected: Post‑nephrectomy ccRCC at intermediate‑high/high risk and M1 NED cohorts—broadening benefit beyond classic localized high‑risk groups. (read more)
  • Theme 2: Post–PD-(L)1 Sequencing With HIF-2α + VEGFR TKI
    • Significance: In advanced ccRCC after immune checkpoint therapy, belzutifan + LENVIMA (lenvatinib) delivered the first positive phase 3 HIF‑2α/VEGFR TKI combination vs a modern TKI comparator, informing immediate second‑line sequencing. (read more)
    • Mechanism insights / clinical impact: Complementary hypoxia-pathway inhibition plus VEGFR blockade improved PFS (median 14.8 vs 10.7 months; HR 0.70) and ORR vs cabozantinib; class‑specific hypoxia events underscore the need for proactive supportive care. (read more)
    • Patient populations affected: Unresectable/metastatic ccRCC progressing after anti–PD‑(L)1 therapy, including patients previously treated with up to two systemic lines. (read more)
  • Theme 3: Radiotherapeutics Enter RCC Combinations
    • Significance: CAIX‑targeted radioligand therapy is moving from diagnostic to therapeutic combinations in RCC, signaling a new modality that could deepen disease control when paired with TKI/IO backbones. (read more)
    • Mechanism insights / clinical impact: 177Lu‑girentuximab (TLX250‑Tx) delivers β‑radiation to CAIX‑expressing ccRCC; STARLITE‑1 (cabozantinib + nivolumab + 177Lu‑girentuximab) explores triplet synergy in treatment‑naive advanced disease (trial‑in‑progress). (read more)
    • Patient populations affected: Treatment‑naive advanced ccRCC with CAIX expression—an emerging biomarker‑selected group for radiotheranostic strategies. (read more)
  • Significance
    • Expected clinical or translational readouts: Final OS from LITESPARK‑011; continued OS follow‑up for LITESPARK‑022; early safety/feasibility from radioligand‑based combinations (inference based on trial status and press program). (read more)
    • Regulatory or policy implications: FDA accepted sNDAs for belzutifan + lenvatinib with PDUFA target October 4, 2026; priority review accepted for adjuvant belzutifan + pembrolizumab—both pointing to near‑term label expansions. (read more)
    • Potential shifts in standard of care: Adjuvant doublet could supersede pembrolizumab alone in high‑risk post‑nephrectomy ccRCC; in the post–PD‑(L)1 setting, belzutifan + lenvatinib may displace single‑agent TKIs. (read more)
    • Strategic implications: HIF‑2α becomes a combination hub across disease stages; programs that manage anemia/hypoxia and integrate oral regimens may gain adoption advantages; early investment in CAIX‑directed radiotherapeutics and companion imaging could open new RCC segments (inference).
Publications Related to Approved Drugs
Unknown Drug
There are no new publication updates during the 2026-02-01 to 2026-02-28 for renal cell carcinoma.
New Publications Related to Drugs in Clinical Trial Development
Phase 1/Phase 2
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. This Phase 1/2 substudy evaluated novel pembrolizumab-based combinations in treatment-naive advanced clear-cell renal cell carcinoma, reporting a 77.5% objective response rate and a median progression-free survival of 31.8 months for the triplet of pembrolizumab, lenvatinib, and belzutifan. While the efficacy was robust, the triplet performed similarly to the doublet control arm, and the specific contribution of belzutifan in this setting is being further defined in the ongoing Phase 3 LITESPARK-012 study. ()
Phase 3
Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future? This narrative review analyzed 12 retrospective studies regarding the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma treated with immune-checkpoint inhibitors, noting a survival benefit associated with CN in half of the studies, particularly in the upfront setting. The authors conclude that while retrospective signals are positive, definitive practice changes regarding the timing and necessity of CN await readouts from ongoing randomized trials such as PROBE (SWOG-1931). ()
Phase 2
Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies. In this Phase 2 basket trial targeting ARID1A-deficient solid tumors, the ATR inhibitor ceralasertib demonstrated a 14% objective response rate, with all confirmed responses restricted to gynecologic malignancies. Although the study enrolled various solid tumors, the lack of responses outside of endometrial and ovarian carcinomas suggests that ceralasertib monotherapy may have limited activity in other ARID1A-deficient solid tumor types. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in renal cell carcinoma updated from 2026-02-01 to 2026-02-28:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting313-3111
Recruiting1389-4-34
Available-------
Approved for Marketing-------
Active, Not Recruiting535-1-14
Completed----1-1
Total211217-9160
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Zimberelimab, AB598, Oxaliplatin, Fluorouracil, Leucovorin NCT05891171 ACTIVE_NOT_RECRUITING A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies 2026-03
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
No phase 2 trials completing within the next three months.
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Sunitinib, Axitinib, : Pembrolizumab NCT02853331 COMPLETED A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) 2025-12-26
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.